Israeli Medical Device Firm Filterlex Medical Files for Liquidation Due to Debt
Translated & summarized from Ice by baba
The story in 5 lines · by baba
- Filterlex Medical filed for liquidation with 1.3 million shekels in debt.
- The company developed a cardiology system to prevent strokes during catheterization.
- Competitor study results questioned the clinical need for such devices.
- Attempts to secure funding or sell intellectual property failed.
- The European Union is the largest creditor.
Israeli medical device company Filterlex Medical has filed a request with the Haifa District Court to initiate liquidation proceedings, citing debts of approximately 1.3 million shekels. The company, which developed a cardiology system, has ceased operations and currently has no employees, revenue, or funding sources. Its shareholder and director is Dr. Shimon Ekhauz, a co-founder of Lumenis.
Founded in 2015, Filterlex developed CAPTIS, a system designed to prevent embolisms during cardiac catheterization procedures, such as transcatheter aortic valve replacement (TAVI). The system aimed to reduce the risk of particles released during procedures causing neurological damage or stroke. The company's activities were financed through investments and R&D grants, typical for early-stage medical startups.
According to the court filing, the company failed to reach the revenue-generating stage. It continued development until early 2025, with its product undergoing clinical trials in Israel. In February 2025, the FDA approved the commencement of clinical trials in the US for the second generation of the system.
However, the landscape shifted following the publication of results from a large-scale study on a competing product, Sentinel, by Boston Scientific. These findings indicated low efficacy for products like Filterlex's, raising questions about the clinical need and commercial potential for stroke prevention during cardiac catheterizations. Despite hopes for further clinical data to alter this perception, the company's request states these hopes were not realized.
Consequently, the company's board decided to freeze operations. Attempts to find a strategic buyer for the company's intellectual property were unsuccessful. Since June 2025, the company has been managed by a CEO working without salary. Filterlex is now seeking court approval to enter insolvency proceedings and appoint a trustee for its liquidation. The filing indicates that the majority of the debt, totaling around 1.3 million shekels, is owed to the European Union. The company's attorneys cited the clinical findings that undermined the field's potential and the lack of a funding source or alternative buyer as the reasons for its predicament.
Mentioned
